Symbols / AMRN Stock $14.95 -0.47% Amarin Corporation plc

Healthcare • Drug Manufacturers - General • Ireland • NCM
AMRN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - General
CEO Mr. Aaron D. Berg
Exch · Country NCM · Ireland
Market Cap 313.49M
Enterprise Value 5.97B
Income -33.61M
Sales 216.76M
FCF (ttm) 2.22M
Book/sh 21.42
Cash/sh 0.73
Employees 80
Insider 10d —
IPO Apr 01, 1993
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 15.26
PEG 0.81
P/S 1.45
P/B 0.70
P/C —
EV/EBITDA -2,640.27
EV/Sales 27.54
Quick Ratio 2.31
Current Ratio 3.48
Debt/Eq 1.71
LT Debt/Eq —
EPS (ttm) -1.60
EPS next Y 0.98
EPS Growth —
Revenue Growth 7.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-29
Earnings (prior) 2026-04-29
ROA -0.50%
ROE -7.28%
ROIC —
Gross Margin 52.36%
Oper. Margin -17.75%
Profit Margin -15.51%
Shs Outstand 20.97M
Shs Float 370.33M
Insider Own 1.97%
Instit Own 22.87%
Short Float 3.28%
Short Ratio 10.25
Short Interest 673.97K
52W High 20.90
vs 52W High -28.47%
52W Low 9.98
vs 52W Low 49.80%
Beta 0.82
Impl. Vol. 0.78%
Rel Volume 0.37
Avg Volume 75.34K
Volume 27.69K
Target (mean) $12.50
Tgt Median $12.50
Tgt Low $12.00
Tgt High $13.00
# Analysts 2
Recom Underperform
Prev Close $15.02
Price $14.95
Change -0.47%
About

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.50
Mean price target
2. Current target
$14.95
Latest analyst target
3. DCF / Fair value
$1.91
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.95
Low
$12.00
High
$13.00
Mean
$12.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-06-25 main Goldman Sachs Sell → Sell $12
2025-04-17 main Goldman Sachs Sell → Sell $7
2024-06-20 reit Cantor Fitzgerald — → Overweight —
2024-06-18 reit Cantor Fitzgerald — → Overweight —
2023-10-25 down Jefferies Buy → Hold $1
2023-07-20 main Goldman Sachs Sell → Sell $1
2023-07-19 main Northland Capital Markets Market Perform → Market Perform $1
2023-01-06 up Jefferies Hold → Buy $3
2022-10-19 main SVB Leerink — → Market Perform $2
2022-05-24 main Goldman Sachs — → Sell $2
2022-05-06 down JP Morgan Neutral → Underweight —
2022-05-05 down HC Wainwright & Co. Buy → Neutral $3
2022-05-05 down SVB Leerink Outperform → Market Perform $3
2022-02-16 main SVB Leerink — → Outperform $10
2022-01-31 main SVB Leerink — → Outperform $11
2021-09-09 init SVB Leerink — → Outperform $12
2021-05-12 down Goldman Sachs Neutral → Sell $5
2021-02-01 main SVB Leerink — → Outperform $16
2020-09-28 main SVB Leerink — → Outperform $12
2020-08-26 init Piper Sandler — → Overweight $21
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-17 KOSTAS ODYSSEAS D. Director — 838 — —
2026-04-17 HORN KEITH L. Director — 838 — —
2026-04-17 BONFIGLIO PATRICE EADON Director — 838 — —
2026-04-17 COHEN PAUL Director — 838 — —
2026-04-17 SULLIVAN DIANE E Director — 838 — —
2026-04-17 O'CONNOR OLIVER Director — 838 — —
2026-04-17 STERLING LOUIS EMERSON III Director — 838 — —
2026-04-01 FISHMAN PETER L Chief Financial Officer — 125 — —
2026-01-30 KETCHUM STEVEN B Officer — 4,179 — —
2026-01-30 BERG AARON D. Chief Executive Officer — 4,179 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
213.65
-6.55%
228.61
-25.51%
306.91
-16.87%
369.19
Operating Revenue
213.65
-6.55%
228.61
-25.51%
306.91
-16.87%
369.19
Cost Of Revenue
92.78
-36.99%
147.23
+4.15%
141.37
+11.57%
126.71
Reconciled Cost Of Revenue
92.78
-36.99%
147.23
+4.15%
141.37
+11.57%
126.71
Gross Profit
120.87
+48.52%
81.38
-50.84%
165.54
-31.73%
242.48
Operating Expense
134.81
-22.16%
173.18
-22.05%
222.16
-33.65%
334.83
Research And Development
19.81
-5.09%
20.87
-6.08%
22.22
-26.94%
30.41
Selling General And Administration
115.00
-24.49%
152.31
-23.82%
199.94
-34.32%
304.42
Selling And Marketing Expense
40.59
-49.00%
79.59
-28.51%
111.33
-40.02%
185.61
General And Administrative Expense
74.41
+2.32%
72.72
-17.93%
88.61
-25.41%
118.80
Salaries And Wages
9.24
-34.75%
14.17
+13.39%
12.49
-44.08%
22.34
Other Gand A
65.17
+11.29%
58.56
-23.07%
76.12
-21.09%
96.46
Total Expenses
227.59
-28.97%
320.41
-11.86%
363.53
-21.24%
461.54
Operating Income
-13.94
+84.81%
-91.80
-62.14%
-56.62
+38.69%
-92.34
Total Operating Income As Reported
-50.17
+45.35%
-91.80
-35.82%
-67.59
+36.16%
-105.87
EBITDA
-33.01
+55.50%
-74.18
-46.32%
-50.70
+49.65%
-100.69
Normalized EBITDA
3.22
+104.34%
-74.18
-86.73%
-39.73
+54.43%
-87.17
Reconciled Depreciation
3.03
+0.50%
3.01
+1.62%
2.96
-4.23%
3.10
EBIT
-36.04
+53.31%
-77.19
-43.85%
-53.66
+48.30%
-103.79
Total Unusual Items
-36.23
0.00
+100.00%
-10.97
+18.88%
-13.53
Total Unusual Items Excluding Goodwill
-36.23
0.00
+100.00%
-10.97
+18.88%
-13.53
Special Income Charges
-36.23
0.00
+100.00%
-10.97
+18.88%
-13.53
Restructuring And Mergern Acquisition
36.23
0.00
-100.00%
10.97
-18.88%
13.53
Net Income
-38.80
+52.79%
-82.18
-39.03%
-59.11
+44.13%
-105.80
Pretax Income
-36.05
+53.31%
-77.20
-43.84%
-53.67
+48.30%
-103.81
Net Non Operating Interest Income Expense
10.85
-19.04%
13.40
+13.00%
11.86
+322.79%
2.80
Interest Expense Non Operating
0.01
+0.00%
0.01
-12.50%
0.01
-46.67%
0.01
Net Interest Income
10.85
-19.04%
13.40
+13.00%
11.86
+322.79%
2.80
Interest Expense
0.01
+0.00%
0.01
-12.50%
0.01
-46.67%
0.01
Interest Income Non Operating
10.85
-19.03%
13.40
+12.98%
11.86
+320.82%
2.82
Interest Income
10.85
-19.03%
13.40
+12.98%
11.86
+320.82%
2.82
Other Income Expense
-32.95
-2843.80%
1.20
+113.48%
-8.91
+37.55%
-14.27
Other Non Operating Income Expenses
3.28
+172.77%
1.20
-41.78%
2.06
+378.78%
-0.74
Tax Provision
2.75
-44.81%
4.98
-8.43%
5.44
+172.37%
2.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-7.61
0.00
+100.00%
-2.30
+18.88%
-2.84
Net Income Including Noncontrolling Interests
-38.80
+52.79%
-82.18
-39.03%
-59.11
+44.13%
-105.80
Net Income From Continuing Operation Net Minority Interest
-38.80
+52.79%
-82.18
-39.03%
-59.11
+44.13%
-105.80
Net Income From Continuing And Discontinued Operation
-38.80
+52.79%
-82.18
-39.03%
-59.11
+44.13%
-105.80
Net Income Continuous Operations
-38.80
+52.79%
-82.18
-39.03%
-59.11
+44.13%
-105.80
Normalized Income
-10.18
+87.62%
-82.18
-62.92%
-50.44
+46.97%
-95.12
Net Income Common Stockholders
-38.80
+52.79%
-82.18
-39.03%
-59.11
+44.13%
-105.80
Diluted EPS
-1.80
+55.00%
-4.00
-33.33%
-3.00
+42.31%
-5.20
Basic EPS
-1.80
+55.00%
-4.00
-33.33%
-3.00
+42.31%
-5.20
Basic Average Shares
20.75
+0.98%
20.55
+0.81%
20.38
+1.62%
20.06
Diluted Average Shares
20.75
+0.98%
20.55
+0.81%
20.38
+1.62%
20.06
Diluted NI Availto Com Stockholders
-38.80
+52.79%
-82.18
-39.03%
-59.11
+44.13%
-105.80
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
670.77
-2.13%
685.35
-17.60%
831.68
-6.15%
886.18
Current Assets
649.88
+9.15%
595.40
-17.87%
724.98
+5.21%
689.10
Cash Cash Equivalents And Short Term Investments
302.59
+2.84%
294.22
-8.25%
320.66
+3.65%
309.36
Cash And Cash Equivalents
134.66
+11.25%
121.04
-39.25%
199.25
-8.46%
217.67
Other Short Term Investments
167.93
-3.03%
173.18
+42.65%
121.41
+32.40%
91.69
Receivables
126.83
+3.72%
122.28
-8.45%
133.56
+1.96%
130.99
Accounts Receivable
126.83
+3.72%
122.28
-8.45%
133.56
+1.96%
130.99
Gross Accounts Receivable
144.98
+8.95%
133.07
-17.19%
160.69
-14.26%
187.42
Allowance For Doubtful Accounts Receivable
-18.15
-68.17%
-10.79
+60.21%
-27.12
+51.93%
-56.43
Inventory
195.91
+17.98%
166.05
-35.79%
258.62
+13.07%
228.73
Raw Materials
112.29
—
—
—
Work In Process
8.20
—
—
—
Finished Goods
75.42
—
—
—
Prepaid Assets
—
—
—
—
Restricted Cash
0.20
-33.00%
0.30
-42.86%
0.53
+0.38%
0.52
Other Current Assets
24.35
+93.99%
12.55
+8.04%
11.62
-40.40%
19.49
Total Non Current Assets
20.89
-76.77%
89.95
-15.70%
106.70
-45.86%
197.08
Net PPE
6.47
-14.92%
7.61
-9.69%
8.42
-15.32%
9.95
Gross PPE
7.95
-12.46%
9.08
-7.40%
9.80
-21.07%
12.42
Accumulated Depreciation
-1.47
-0.27%
-1.47
-6.60%
-1.38
+44.22%
-2.47
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
—
—
—
9.07
Machinery Furniture Equipment
1.27
+0.00%
1.27
-0.55%
1.28
-48.49%
2.48
Other Properties
6.46
-14.90%
7.59
-8.64%
8.31
-8.42%
9.07
Leases
0.22
+0.00%
0.22
+0.00%
0.22
-75.03%
0.87
Goodwill And Other Intangible Assets
13.37
-18.45%
16.39
-15.10%
19.30
-11.37%
21.78
Other Intangible Assets
13.37
-18.45%
16.39
-15.10%
19.30
-11.37%
21.78
Investments And Advances
—
—
0.00
-100.00%
1.27
Other Non Current Assets
1.05
-98.40%
65.95
-16.49%
78.97
-51.87%
164.08
Total Liabilities Net Minority Interest
211.49
+6.19%
199.17
-28.76%
279.59
-3.87%
290.85
Current Liabilities
194.46
+8.06%
179.95
-30.60%
259.28
-0.08%
259.48
Payables And Accrued Expenses
176.12
+8.45%
162.40
-30.57%
233.91
+5.54%
221.64
Payables
45.35
+12.36%
40.37
-23.49%
52.76
-18.33%
64.60
Accounts Payable
45.35
+12.36%
40.37
-23.49%
52.76
-18.33%
64.60
Current Accrued Expenses
130.77
+7.15%
122.04
-32.63%
181.15
+15.36%
157.03
Current Deferred Liabilities
—
0.00
-100.00%
2.34
+6.46%
2.20
Current Deferred Revenue
—
0.00
-100.00%
2.34
+6.46%
2.20
Other Current Liabilities
18.34
+4.52%
17.55
-23.79%
23.02
-35.41%
35.64
Total Non Current Liabilities Net Minority Interest
17.04
-11.39%
19.22
-5.35%
20.31
-35.25%
31.37
Long Term Debt And Capital Lease Obligation
6.08
-21.27%
7.72
-11.61%
8.74
-12.76%
10.02
Long Term Capital Lease Obligation
6.08
-21.27%
7.72
-11.61%
8.74
-12.76%
10.02
Non Current Deferred Liabilities
—
0.00
-100.00%
2.51
-80.92%
13.15
Non Current Deferred Revenue
—
0.00
-100.00%
2.51
-80.92%
13.15
Other Non Current Liabilities
10.96
-4.75%
11.50
+26.89%
9.06
+10.47%
8.21
Stockholders Equity
459.28
-5.53%
486.18
-11.94%
552.10
-7.26%
595.33
Common Stock Equity
459.28
-5.53%
486.18
-11.94%
552.10
-7.26%
595.33
Capital Stock
310.18
+1.60%
305.30
+0.84%
302.76
+1.26%
299.00
Common Stock
310.18
+1.60%
305.30
+0.84%
302.76
+1.26%
299.00
Share Issued
429.85
+1.80%
422.26
+0.98%
418.14
+1.41%
412.33
Ordinary Shares Number
416.21
+1.12%
411.58
+0.68%
408.82
+1.11%
404.35
Treasury Shares Number
13.63
+27.75%
10.67
+14.54%
9.32
+16.66%
7.99
Additional Paid In Capital
1,923.80
+0.47%
1,914.75
+0.81%
1,899.46
+0.75%
1,885.35
Retained Earnings
-1,707.34
-2.33%
-1,668.55
-5.18%
-1,586.36
-3.87%
-1,527.25
Treasury Stock
67.36
+3.11%
65.33
+2.47%
63.75
+3.21%
61.77
Total Equity Gross Minority Interest
459.28
-5.53%
486.18
-11.94%
552.10
-7.26%
595.33
Total Capitalization
459.28
-5.53%
486.18
-11.94%
552.10
-7.26%
595.33
Working Capital
455.42
+9.62%
415.45
-10.79%
465.70
+8.40%
429.62
Invested Capital
459.28
-5.53%
486.18
-11.94%
552.10
-7.26%
595.33
Total Debt
6.08
-21.27%
7.72
-11.61%
8.74
-12.76%
10.02
Capital Lease Obligations
6.08
-21.27%
7.72
-11.61%
8.74
-12.76%
10.02
Net Tangible Assets
445.92
-5.08%
469.79
-11.83%
532.79
-7.11%
573.55
Tangible Book Value
445.92
-5.08%
469.79
-11.83%
532.79
-7.11%
573.55
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
6.73
+121.69%
-31.02
-550.87%
6.88
+103.82%
-180.09
Cash Flow From Continuing Operating Activities
6.73
+121.69%
-31.02
-550.87%
6.88
+103.82%
-180.09
Net Income From Continuing Operations
-38.80
+52.79%
-82.18
-39.03%
-59.11
+44.13%
-105.80
Depreciation Amortization Depletion
3.03
+0.50%
3.01
+1.62%
2.96
-4.23%
3.10
Depreciation
0.00
-95.92%
0.10
-38.75%
0.16
-70.96%
0.55
Amortization Cash Flow
3.02
+3.74%
2.92
+3.92%
2.81
+10.22%
2.54
Depreciation And Amortization
3.03
+0.50%
3.01
+1.62%
2.96
-4.23%
3.10
Amortization Of Intangibles
3.02
+3.74%
2.92
+3.92%
2.81
+10.22%
2.54
Stock Based Compensation
13.94
-21.28%
17.70
+13.16%
15.65
-40.31%
26.21
Change In Working Capital
32.21
-10.97%
36.17
-29.18%
51.08
+149.08%
-104.07
Change In Receivables
-3.83
-134.11%
11.21
+582.32%
-2.33
-107.04%
33.00
Changes In Account Receivables
-4.55
-140.35%
11.28
+538.55%
-2.57
-107.88%
32.66
Change In Inventory
34.88
-66.92%
105.44
+87.89%
56.12
+254.09%
-36.42
Change In Prepaid Assets
-12.46
-1233.62%
-0.93
-111.86%
7.87
+175.31%
2.86
Change In Payables And Accrued Expense
14.51
+118.85%
-76.99
-46843.29%
-0.16
+99.84%
-102.73
Change In Accrued Expense
—
—
—
0.00
Change In Payable
14.51
+118.85%
-76.99
-46843.29%
-0.16
+99.84%
-102.73
Change In Account Payable
14.51
+118.85%
-76.99
-46843.29%
-0.16
+99.84%
-102.73
Change In Other Working Capital
—
-4.85
+53.79%
-10.50
-670.07%
-1.36
Change In Other Current Assets
0.16
+7.48%
0.15
+152.88%
-0.28
-13800.00%
-0.00
Change In Other Current Liabilities
-1.06
-149.42%
2.14
+520.58%
0.34
-40.62%
0.58
Investing Cash Flow
8.83
+119.20%
-45.98
-80.14%
-25.52
-114.56%
175.29
Cash Flow From Continuing Investing Activities
8.83
+119.20%
-45.98
-80.14%
-25.52
-114.56%
175.29
Net PPE Purchase And Sale
0.00
0.00
+100.00%
-0.02
0.00
Purchase Of PPE
0.00
0.00
+100.00%
-0.02
0.00
Capital Expenditure
—
—
-0.53
+11.02%
-0.60
Net Investment Purchase And Sale
8.83
+119.20%
-45.98
-83.98%
-24.99
-114.21%
175.89
Purchase Of Investment
-200.47
+28.09%
-278.78
-29.60%
-215.10
-163.49%
-81.63
Sale Of Investment
209.30
-10.09%
232.80
+22.46%
190.11
-26.18%
257.52
Net Intangibles Purchase And Sale
0.00
0.00
+100.00%
-0.51
+15.03%
-0.60
Purchase Of Intangibles
0.00
0.00
+100.00%
-0.51
+15.03%
-0.60
Financing Cash Flow
-2.03
-40.96%
-1.44
-727.39%
0.23
+160.69%
-0.38
Cash Flow From Continuing Financing Activities
-2.03
-40.96%
-1.44
-727.39%
0.23
+160.69%
-0.38
Net Issuance Payments Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
—
0.00
Long Term Debt Payments
—
—
—
0.00
Net Long Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
—
—
—
—
Proceeds From Stock Option Exercised
0.14
+6.87%
0.13
-94.08%
2.21
+232.63%
0.67
Net Other Financing Charges
-2.17
-38.12%
-1.57
+20.59%
-1.98
-89.85%
-1.04
Changes In Cash
13.52
+117.24%
-78.44
-326.02%
-18.41
-255.24%
-5.18
Beginning Cash Position
121.34
-39.26%
199.78
-8.44%
218.19
-2.32%
223.37
End Cash Position
134.86
+11.14%
121.34
-39.26%
199.78
-8.44%
218.19
Free Cash Flow
6.73
+121.69%
-31.02
-588.73%
6.35
+103.51%
-180.69
Interest Paid Supplemental Data
—
—
—
0.00
Income Tax Paid Supplemental Data
1.00
-74.89%
3.98
+68.23%
2.37
+32.83%
1.78
Amortization Of Securities
-3.65
+36.36%
-5.73
-55.01%
-3.70
-881.40%
0.47
Change In Interest Payable
—
—
—
0.00
Common Stock Issuance
—
—
—
—
Issuance Of Capital Stock
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category